Tsutomu Ogata1, Maki Fukami1, Yuka Wada1. 1. Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, Tokyo, Japan.
Abstract
MAMLD1 (mastermind-like domain containing 1), previously known as CXorf6 (chromosome X open reading frame 6), has been shown to be a causative gene for hypospadias. This is primarily based on the identification of nonsense mutations (E124X, Q197X, and R653X), which undergo nonsense mediated mRNA decay, in patients with penoscrotal hypospadias. Subsequent molecular studies have shown that the mouse homolog is transiently expressed in fetal Sertoli and Leydig cells around the critical period for sex development, and that transient knockdown of Mamld1 results in significantly reduced testosterone production in murine Leydig tumor cells. These findings suggest that the MAMLD1 mutations cause hypospadias primarily because of compromised testosterone production around the critical period for sex development.
MAMLD1 (mastermind-like domain containing 1), previously known as CXorf6 (chromosome X open reading frame 6), has been shown to be a causative gene for hypospadias. This is primarily based on the identification of nonsense mutations (E124X, Q197X, and R653X), which undergo nonsense mediated mRNA decay, in patients with penoscrotal hypospadias. Subsequent molecular studies have shown that the mouse homolog is transiently expressed in fetal Sertoli and Leydig cells around the critical period for sex development, and that transient knockdown of Mamld1 results in significantly reduced testosterone production in murineLeydig tumor cells. These findings suggest that the MAMLD1 mutations cause hypospadias primarily because of compromised testosterone production around the critical period for sex development.
Hypospadias is defined by the urethral opening on the ventral side of the penis, and is
classified into mild glandular or penile type and severe penoscrotal or perineal type (1). It is a mild form of 46,XY disorders of sex
development (DSD), and affects approximately 0.5% of male newborns (2). Hypospadias is primarily caused by compromised androgen effects, and
appears as an isolated anomaly or in association with other genital anomalies such as
micropenis and cryptorchidism. To date, while mutation analyses have been performed for
multiple genes involved in androgen effects such as SRD5A2 for 5-alpha-redeuctase and AR for
androgen receptor, pathologic mutations have been identified in only a very small portion of
patients (2). This would be consistent with
hypospadias being a highly heterogeneous condition subject to multiple genetic and
environmental factors.We have recently shown that CXorf6 (chromosome X open reading frame 6) is a novel gene for
hypospadias (3), and coined a new gene symbol MAMLD1
(mastermind-like domain containing, 1) on the basis of its characteristic protein structure
with homology to mastermind like 2 (MAML2) protein (4). Herein, we review the current knowledge about MAMLD1.
Cloning of a Candidate Gene for 46,XY DSD
A gene for 46,XY DSD has been postulated around MTM1 for myotubular myopathy on Xq28, on
the basis of the finding that genital development was normal in patients with intragenic
MTM1 mutations, and invariably abnormal in six patients with microdeletions involving MTM1
(5,6,7,8). The six
patients consisted of three sporadic and three familial cases, and five of them have
glandular, penile, or penoscrotal hypospadias; the remaining one exhibits ambiguous
genitalia (5,6,7). These findings suggest that a gene for
46,XY DSD, especially that for hypospadias, resides in the vicinity of MTM1, and that loss
or disruption of the gene results in the development of 46,XY DSD as consequence of
contiguous gene deletion syndrome.In 1997, Laporte et al. (9) identified MAMLD1 from a
430-kb region deleted in two sporadic cases with myotubular myopathy and 46,XY DSD (7). MAMLD1 comprises at least seven exons, and harbors an
open reading frame on exons 3–6 that is predicted to produce two proteins of 701 and 660
amino acids as a result of in-frame alternative splicing with and without exon 4.
Furthermore, subsequent studies have shown loss of MAMLD1 in all patients with myotubular
myopathy and 46,XY DSD (our unpublished observation), and no other candidate gene for 46,XY
DSD has been identified within the commonly deleted region. These findings imply that MAMLD1
is an excellent candidate gene for 46,XY DSD, especially hypospadias.
MAMLD1 Mutations in Hypospadiac Patients
We performed direct sequencing for the coding exons 3–6 and their flanking splice sites of
MAMLD1 in 166 patients including 56 cases with hypospadias. Consequently, three nonsense
mutations were identified in Japanese patients with hypospadias: E124X in maternally related
half brothers from family A (cases 1 and 2), Q197X in a patient from family B (case 3), and
R653X in a patient from family C (case 4) (Fig.
1) (3). The mothers of families A and C were
heterozygous for the mutations, although the mother of family B was not studied.
Fig. 1.
The pedigrees and electrochromatograms of Japanese patients with nonsense mutations
(A–C). The black squares indicate the patients with 46,XY DSD and the mutant MAMLD1,
and the circles with dots represent molecularly confirmed carrier females. The
asterisks in the chromatograms indicate the mutant and corresponding wildtype
nucleotides. N.E.: not examined.
The pedigrees and electrochromatograms of Japanese patients with nonsense mutations
(A–C). The black squares indicate the patients with 46,XY DSD and the mutant MAMLD1,
and the circles with dots represent molecularly confirmed carrier females. The
asterisks in the chromatograms indicate the mutant and corresponding wildtype
nucleotides. N.E.: not examined.
Nonsense Mediated mRNA Decay (NMD)
One may argue that the hypospadias in case 4 with R653X on exon 5 is inconsistent with the
apparently normal genital development in a previously reported boy with a microdeletion
involving MTM1 that has resulted in generation of a fusion gene between exons 1–4 of CXorf6
and exons 3–16 of MAMLD1 (locus order: CXorf6-MTM1-MTMR1), because the coding exons 3 and 4
are preserved in both case 4 and the boy with the fusion gene (10) (Fig. 2). However, in contrast to the positive expression of the fusion gene confirmed in the
biopsied muscle tissue (10), the three nonsense
mutations are predicted to cause NMD because of their positions (11). Consistent with this, RT-PCR for leukocytes indicated drastically
reduced transcripts in cases 1–4 (Fig. 3). Furthermore, NMD was protected by an NMD inhibitor cycloheximide, providing further
support for the occurrence of NMD in the three nonsense mutations (3, 4). Thus, although NMD has not
been confirmed in the testicular tissue, the results explain the apparent discordance in the
genital development between case 4 and the boy described by Tsai et al. (10), and indicate that the three nonsense mutations
including R653X are pathologic mutations.
Fig. 2.
Schematic representation of the R653X mutation in case 4 and the fusion gene between
MAMLD1 and MTMR1. The black and the white squares in MAMLD1 indicate the translated
and untranslated regions, respectively.
Fig. 3.
NMD analysis. Upper part: The black and gray boxes represent the coding regions, and
the open boxes denote the untranslated regions. The positions of the mutations and
variations are shown. RT-PCR for the two regions (RT-PCR-1 and -2) has produced no
bands after 30 cycles and very faint bands after 40 cycles in cases 1–4. Lower part:
NMD analysis in case 4 with and without an NMD inhibitor cycloheximide (CHX). After 40
cycles of RT-PCR for the region 1, no band is seen without CHX treatment, and a clear
band is delineated with CHX treatment.
Schematic representation of the R653X mutation in case 4 and the fusion gene between
MAMLD1 and MTMR1. The black and the white squares in MAMLD1 indicate the translated
and untranslated regions, respectively.NMD analysis. Upper part: The black and gray boxes represent the coding regions, and
the open boxes denote the untranslated regions. The positions of the mutations and
variations are shown. RT-PCR for the two regions (RT-PCR-1 and -2) has produced no
bands after 30 cycles and very faint bands after 40 cycles in cases 1–4. Lower part:
NMD analysis in case 4 with and without an NMD inhibitor cycloheximide (CHX). After 40
cycles of RT-PCR for the region 1, no band is seen without CHX treatment, and a clear
band is delineated with CHX treatment.
Phenotypes in Mutation Positive Patients
Cases 1–4 had penoscrotal hypospadias with chordee as the conspicuous genital phenotype, in
association with other genital phenotypes (Table
1). Pituitary-gonadal serum hormone values remained within the normal range,
including the human chorionic gonadotropin (hCG)-stimulated testosterone value in case 1 at
two years and five mo of age, and the basal testosterone values in case 2 at one mo of age
and in case 4 at three mo of age when serum testosterone is physiologically elevated. Thus,
the diagnosis of idiopathic hypospadias was initially made in cases 1–4. It was suspected
that testosterone production was compromised only during fetal life, or that external
genitalia had defective development of anlagen or impaired responsiveness to testosterone.
While placental dysfunction could also affect male genital development by attenuating the
production of hCG (2), there was no pregnant episode
suggestive of placental dysfunction.
Table 1.
Clinical findings of the four Japanese cases with MAMLD1 nonsense
mutations
In situ Hybridization (ISH) Analysis for Mouse Mamld1
ISH analysis for mouseMamld1 showed cell type-specific expression pattern (3). Namely, Mamld1 is specifically and transiently
expressed in Sertoli and Leydig cells around the critical period for sex development
(E12.5–E14.5) (Fig. 4). This expression pattern has been confirmed by double staining with antibodies for
Ad4bp/Sf-1 that serves as a marker for Sertoli and Leydig cells. In extragonadal tissues at
E12.5, Mamld1 expression was absent in the adrenals and weakly and diffusely identified in
the external genital region including the genital tubercle at a level similar to that
detected in the neighboring extragenital tissues (Fig.
2B). Mamld1 was also clearly expressed in the Müllerian ducts, forebrain, somite,
neural tube, and pancreas. By contrast, Mamld1 expression was absent in the postnatal
testes. These data imply that nonsense mutations of MAMLD1 cause hypospadias primarily
because of transient testicular dysfunction and resultant compromised testosterone
production around the critical period for sex development, and explain why postnatal
endocrine data were normal in cases 1–4.
Fig. 4.
In situ hybridization analysis of the murine Mamld1. A. Expression patterns in the
fetal testes at E12.5 and E14.5. The blue signals are derived from in situ
hybridization for Mamld1, and the brown signals from immunohistochemical staining with
Sf-1 (Ad4bp) antibodies. m: mesonephros; G: germ cell; S: Sertoli cell; and L: Leydig
cell. The scale bars in the low and high power fields represent 200 µm and 20 µm,
respectively. B. Expression patterns in the fetal adrenal (upper part) and external
genitalia (lower part) of male mouse at E12.5. m: mesonephros; g; gonad; ad: adrenal;
and GT: genital tubercle (the between two arrows). MAMLD1 is not expressed in the
adrenal, and weakly and diffusely expressed in the external genitalia as in other
non-genital skin tissues.
In situ hybridization analysis of the murineMamld1. A. Expression patterns in the
fetal testes at E12.5 and E14.5. The blue signals are derived from in situ
hybridization for Mamld1, and the brown signals from immunohistochemical staining with
Sf-1 (Ad4bp) antibodies. m: mesonephros; G: germ cell; S: Sertoli cell; and L: Leydig
cell. The scale bars in the low and high power fields represent 200 µm and 20 µm,
respectively. B. Expression patterns in the fetal adrenal (upper part) and external
genitalia (lower part) of male mouse at E12.5. m: mesonephros; g; gonad; ad: adrenal;
and GT: genital tubercle (the between two arrows). MAMLD1 is not expressed in the
adrenal, and weakly and diffusely expressed in the external genitalia as in other
non-genital skin tissues.
Function of Mamld1 in Testosterone Production
We performed knockdown analysis with siRNAs for Mamld1, using mouseLeydig tumor (MLT)
cells that retain the capability of testosterone production and the responsiveness to hCG
stimulation (4). When the mRNA level of endogenous
Mamld1 was severely reduced in the mouseLeydig tumor cells (25–30%), testosterone
production was decreased to 50–60% of the previous level after 48 h of incubation and one h
after hCG stimulation. This implies that MAMLD1 is involved in the testosterone
biosynthesis. Furthermore, since testosterone production would probably be attenuated rather
than abolished in the absence of MAMLD1, this is consistent with the hypospadias phenotype
in the affected patients (2).
Conclusions
MAMLD1 is a causative gene for hypospadias, and possibly other forms of 46,XY DSD. It
appears to play a supportive role in the testosterone production around the critical period
for sex development. Further studies including knockout mouse experiments will permit to
clarify MAMLD1 dependent molecular network involved in testosterone production.
Authors: J Laporte; C Guiraud-Chaumeil; M C Vincent; J L Mandel; S M Tanner; S Liechti-Gallati; C Wallgren-Pettersson; N Dahl; W Kress; P A Bolhuis; M Fardeau; F Samson; E Bertini Journal: Hum Mol Genet Date: 1997-09 Impact factor: 6.150
Authors: L J Hu; J Laporte; W Kress; P Kioschis; R Siebenhaar; A Poustka; M Fardeau; A Metzenberg; E A Janssen; N Thomas; J L Mandel; N Dahl Journal: Hum Mol Genet Date: 1996-01 Impact factor: 6.150